坎格瑞洛全剂量在急性治疗小型破裂脑动脉瘤伴血流导向装置中的应用:单中心经验
该单中心回顾性研究评估了2020年1月至2024年2月间10例小型(小于6 mm)破裂脑动脉瘤患者急诊置入血流导向装置(FD)前使用坎格瑞洛联合阿司匹林的安全性和有效性;结果显示术后24小时内无血栓栓塞或出血并发症,60%患者预后良好(mRS 0-2),12个月随访动脉瘤完全闭塞率为71.5%(5/7)。
要点
- 10例小型破裂脑动脉瘤患者急诊FD置入前接受坎格瑞洛(30 µg/kg推注后4 µg/kg/min输注12或24小时)联合阿司匹林300 mg治疗。
- 术后24小时内未报告血栓栓塞或出血并发症。
- 60%患者(6/10)临床预后良好(mRS 0-2),12个月随访动脉瘤完全闭塞率为71.5%(5/7)。
核心结论
- 作者认为在其有限经验中,坎格瑞洛在急性FD置入治疗破裂颅内动脉瘤后预防血栓栓塞并发症方面安全有效;需要更大样本和对比方法的研究才能将坎格瑞洛纳入标准神经血管实践。
研究设计与样本
- 单中心回顾性研究,纳入2020年1月至2024年2月期间因颅内动脉瘤急性破裂导致出血性卒中而接受急诊FD植入的患者,共 retrospectively 评估10例。
主要发现
- 所有患者均在到达医院后5小时内接受治疗,并接受静脉坎格瑞洛(30 µg/kg,推注时间小于1分钟)联合阿司匹林(300 mg),随后根据临床情况以4 µg/kg/分钟输注坎格瑞洛12或24小时。
- 术后24小时内未报告血栓栓塞或出血并发症。
- 10例患者中6例(60%)临床预后良好(mRS 0-2)。
- 7例患者中有5例(71.5%)在12个月随访时经MRA/CTA证实动脉瘤完全闭塞。
关键数值与推荐
- 小型破裂脑动脉瘤定义为小于6 mm。
- 坎格瑞洛给药方案:静脉推注30 µg/kg(小于1分钟),随后4 µg/kg/分钟输注12或24小时。
- 联合阿司匹林300 mg。
- 良好临床预后定义为mRS 0-2。
- 主要评估指标包括抗血小板治疗相关操作并发症、12个月随访动脉瘤完全闭塞率和功能结局(mRS)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量有限(10例)。
- 单中心回顾性研究。
- 需要更大样本和对比方法的研究才能将坎格瑞洛纳入标准神经血管实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This article aims to retrospectively assess the safety, efficacy and feasibility of using intravenous cangrelor in the acute treatment of small ruptured cerebral aneurysms (less than 6 mm) with FD, discussing its potential advantages over traditional antiplatelet agents and its implication on clinical practice. METHODS: This is a single-center retrospective study conducted on patients who underwent emergency FD implantation for hemorrhagic stroke due to acute rupture of intracranial aneurysms between January 2020 and February 2024. Patients were medicated with cangrelor in association with acetylsalicylic acid (ASA) before stent deployment. All patients were treated within 5 h from hospital arrival and received intravenous cangrelor (30 µg/kg administered over less than 1 min) + ASA (300 mg), followed by an infusion of cangrelor at 4 µg/kg/minute for either 12 or 24 h, as per clinical scenario. Procedural complications related to antiplatelet therapy itself, rate of complete aneurysm occlusion at 12-months follow-up and clinical outcome in terms of functional scale (mRS) were evaluated. RESULTS: Ten patients were retrospectively evaluated. The interventions showed a favorable outcome with no reported thromboembolic or hemorrhagic complications within the first 24 h post-procedure. Six out of ten patients (60%) of patients had a good clinical prognosis (mRS 0-2), and MRA/CTA follow-ups indicated a complete resolution of aneurysms in the majority of cases (five out of seven patients (71.5%) occlusion rate at 12 months). CONCLUSION: In our limited experience, cangrelor has proven to be safe and effective in preventing thromboembolic complications after acute FD implantation for ruptured intracranial aneurysms; further studies with larger populations and comparative methodologies are required to incorporate cangrelor into standard neurovascular practice.
引用
- Pelle G, Onori A, Andresciani F, et al. Full dose of cangrelor in the acute treatment of small ruptured cerebral aneurysms with flow diverters: a single center experience. Acta Neurochir (Wien). 2025. PMID: 40167808. doi:10.1007/s00701-025-06504-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。